Medications according to follow-up HDL-C level
| Total population | Propensity-matched population | |||||
| Low HDL-C (n=1585) | High HDL-C (n=1108) | p Value | Low HDL-C (n=990) | High HDL-C (n=990) | p Value | |
| Prior PCI | ||||||
| Aspirin | 776 (49.0) | 507 (45.8) | 0.108 | 377 (42.4) | 389 (42.8) | 0.852 |
| Statin | 304 (21.7) | 226 (22.2) | 0.771 | 184 (20.7) | 200 (22.2) | 0.454 |
| At discharge | ||||||
| Aspirin | 1561 (98.5) | 1097 (99.0) | 0.381 | 982 (99.3) | 980 (99.0) | 0.998 |
| Thienophyridine | 1583 (99.9) | 1105 (99.7) | 0.655 | 877 (99.9) | 892 (99.7) | 0.625 |
| β-blocker | 1099 (69.3) | 729 (65.8) | 0.054 | 695 (70.2) | 662 (66.9) | 0.110 |
| ACEI or ARB | 1184 (74.7) | 809 (73.0) | 0.326 | 719 (72.6) | 738 (74.5) | 0.333 |
| CCB | 350 (22.1) | 316 (28.5) | <0.001 | 259 (26.2) | 253 (25.6) | 0.758 |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; HDL-C, high-density lipoprotein cholesterol; PCI, percutaneous coronary intervention.